Glass House Brands (GLAS) Share-based Compensation (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Share-based Compensation of $4.5 million for Q1 2026, up 114.87% year-over-year from $2.1 million in Q1 2025, and up 5.83% quarter-over-quarter from $4.3 million in Q4 2025.
Glass House Brands (GLAS) Share-based Compensation (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Share-based Compensation for 7 consecutive years, with $4.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 114.87% year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at $15.8 million (up 32.6% YoY), while the FY2025 annual figure was $13.4 million, up 2.32% from the prior year.
- Share-based Compensation grew to $4.5 million in Q1 2026 per GLAS's latest filing, from $4.3 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $4.5 million in Q1 2026 and bottomed at $1.5 million in Q2 2023.
- Historically, Share-based Compensation has averaged $3.0 million across 5 years, with a median of $2.9 million in 2024.
- Annual changes were most pronounced in 2022 — Share-based Compensation surged 323.63% — and 2023, when it slumped 56.12%.
- Glass House Brands' Share-based Compensation stood at $3.8 million in 2022, then plunged by 49.36% to $1.9 million in 2023, then soared by 70.66% to $3.3 million in 2024, then surged by 31.18% to $4.3 million in 2025, then increased by 5.83% to $4.5 million in 2026.
- Business Quant data shows GLAS's Share-based Compensation at $4.5 million in Q1 2026, $4.3 million in Q4 2025, and $4.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Glass House Brands | 837.25 Mn | 818.69 Mn | 15.77 Mn | 4.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.52 Mn |
| Mar 31, 2026 | 4.52 Mn |
| Dec 31, 2025 | 4.27 Mn |
| Dec 31, 2025 | 4.27 Mn |
| Sep 30, 2025 | 4.08 Mn |
| Sep 30, 2025 | 4.08 Mn |
| Jun 30, 2025 | 2.94 Mn |
| Jun 30, 2025 | 2.94 Mn |
| Mar 31, 2025 | 2.11 Mn |
| Mar 31, 2025 | 2.11 Mn |
| Dec 31, 2024 | 3.26 Mn |
| Dec 31, 2024 | 3.26 Mn |
| Sep 30, 2024 | 2.95 Mn |
| Sep 30, 2024 | 2.95 Mn |
| Jun 30, 2024 | 3.62 Mn |
| Jun 30, 2024 | 3.62 Mn |
| Mar 31, 2024 | 3.27 Mn |
| Mar 31, 2024 | 3.27 Mn |
| Dec 31, 2023 | 1.91 Mn |
| Dec 31, 2023 | 1.91 Mn |